Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Zhejiang Heze Pharmaceutical Technology Co. Ltd. currently faces 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit, reflecting a focused prosecution effort. The concentration in one art unit indicates that the subject matter is likely specialized within a specific pharmaceutical classification. This focus allows for a highly specialized prosecution strategy that aligns with the specific technical requirements of the 1 distinct art unit. Practitioners can prioritize resources to address the specific technical niche identified by this art unit assignment.
COFFA, SERGIO is the busiest examiner, currently handling the 1 pending office action. Because there is only 1 distinct examiner involved, the prosecution strategy is highly dependent on this individual's specific review. Practitioners should analyze the 1 distinct art unit's typical timelines and the examiner's history to effectively manage the 1 pending action. Maintaining a consistent and clear line of communication with this 1 distinct examiner is essential for resolving the pending matter efficiently within the biotechnology and pharmaceutical sector. This centralized approach ensures that all legal efforts are concentrated on the specific criteria established by the current examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COFFA, SERGIO | 1 | 61.1% | +32.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18266597 | LONG-ACTING GLUCAGON DERIVATIVE | COFFA, SERGIO | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18266597 | LONG-ACTING GLUCAGON DERIVATIVE | COFFA, SERGIO | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18266597 | LONG-ACTING GLUCAGON DERIVATIVE | COFFA, SERGIO | 1658 | §103§112 | Final Rejection | — | Pending | Jun 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial